[2,8-dihydroxyadenine urolithiasis: case report and literature review]. 2011

Matteo Arancio, and Stefania Ranzoni, and Alessandro Delsignore, and Giuseppe Landi, and Nicola Maffei, and Maurizio Marcato, and Alessandro Mina, and Carlo Martinengo
ASL "NO". S.C. Urologia. Presidi Ospedalieri di Borgomanero ed Arona, Novara - Italy. matteo.arancio@yahoo.it

BACKGROUND 2,8-Dihydroxyadenine (DHA) urolithiasis is a rare type of urinary stone disease secondary to deficiency of adenine phosphoribosyltransferase (APRT) activity, a rare, inherited autosomal recessive disease with an incidental rate from 0.4 to 1.2%. The prevalence is higher among Japanese than other ethnic groups. APRT normally catalyzes the conversion of adenine to adenosine monophosphate and its deficiency results in 2,8-dihydroxyadenine (2,8-DHA) accumulation. This compound is extremely insoluble and its crystallization can lead to stone formation and renal failure. We report the case of 2,8-dihydroxyadenine (DHA) urolithiasis in a 52-year-old male patient. METHODS In December 2008 a 52-year-old Caucasian man was admitted to our hospital with sudden pain in the left lumbar region. Abdominal X-ray did not show any radiopaque urinary stone. I.V. pielography showed a radiolucent left lumbar ureteral (0.6 mm) and renal (1.5 cm) stone. After therapy with tamsulosin, the ureteral stone was excreted. Successful ESWL treatment was performed for renal stone. He presented a clinical history of several episodes of bilateral renal colic and two prior ESWL treatment for radiolucent stones. Chemolitholysis was never successful. RESULTS. Stone analysis by infrared spectroscopy and microscopic examination of urine reveal typical 2,8-DHA crystals. APRT deficiency was detected in the hemolysate of erythrocyte. Partial deficiency of APRT in the patient's relatives showed heterozygosity of the enzyme defect. Allopurinol therapy successfully prevented further stone formation. 20 months later the patient remains stone free. CONCLUSIONS Two types of deficit are commonly distinguished, depending on the level of residual APRT activity. Type I is complete enzyme deficiency. Type II shows residual activity in cell lysates, but enzyme activity is not demonstrable in intact cells. About 78% of the Japanese patients belong to type II. The diagnosis of the disease is based on stone analysis by infrared spectroscopy or microscopic examination of urine, which may reveal typical 2,8-DHA crystals. Molecular approach can identify mutations, which are responsible of this inherited disease. Excessive water intake, restriction of foods with high adenine contents and administration of allopurinol are useful treatments. APRT deficiency is a rare disease but we can consider this pathology in case of recurrent radiolucent stones after chemolitolysis.

UI MeSH Term Description Entries
D007669 Kidney Calculi Stones in the KIDNEY, usually formed in the urine-collecting area of the kidney (KIDNEY PELVIS). Their sizes vary and most contains CALCIUM OXALATE. Kidney Stones,Renal Calculi,Nephrolith,Renal Calculus,Calculi, Kidney,Calculi, Renal,Calculus, Kidney,Calculus, Renal,Kidney Calculus,Kidney Stone,Stone, Kidney,Stones, Kidney
D008096 Lithotripsy The destruction of a calculus of the kidney, ureter, bladder, or gallbladder by physical forces, including crushing with a lithotriptor through a catheter. Focused percutaneous ultrasound and focused hydraulic shock waves may be used without surgery. Lithotripsy does not include the dissolving of stones by acids or litholysis. Lithotripsy by laser is LITHOTRIPSY, LASER. ESWL (Extracorporeal Shockwave Lithotripsy),Electrohydraulic Shockwave Lithotripsy,Extracorporeal Shockwave Lithotripsy,Litholapaxy,Noninvasive Litholapaxy,Percutaneous Ultrasonic Lithotripsy,Ultrasonic Lithotripsy,ESWLs (Extracorporeal Shockwave Lithotripsy),Electrohydraulic Shockwave Lithotripsies,Extracorporeal Shockwave Lithotripsies,Litholapaxies,Litholapaxies, Noninvasive,Litholapaxy, Noninvasive,Lithotripsies,Lithotripsies, Electrohydraulic Shockwave,Lithotripsies, Extracorporeal Shockwave,Lithotripsies, Percutaneous Ultrasonic,Lithotripsies, Ultrasonic,Lithotripsy, Electrohydraulic Shockwave,Lithotripsy, Extracorporeal Shockwave,Lithotripsy, Percutaneous Ultrasonic,Lithotripsy, Ultrasonic,Noninvasive Litholapaxies,Percutaneous Ultrasonic Lithotripsies,Shockwave Lithotripsies, Electrohydraulic,Shockwave Lithotripsies, Extracorporeal,Shockwave Lithotripsy, Electrohydraulic,Shockwave Lithotripsy, Extracorporeal,Ultrasonic Lithotripsies,Ultrasonic Lithotripsies, Percutaneous,Ultrasonic Lithotripsy, Percutaneous
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011859 Radiography Examination of any part of the body for diagnostic purposes by means of X-RAYS or GAMMA RAYS, recording the image on a sensitized surface (such as photographic film). Radiology, Diagnostic X-Ray,Roentgenography,X-Ray, Diagnostic,Diagnostic X-Ray,Diagnostic X-Ray Radiology,X-Ray Radiology, Diagnostic,Diagnostic X Ray,Diagnostic X Ray Radiology,Diagnostic X-Rays,Radiology, Diagnostic X Ray,X Ray Radiology, Diagnostic,X Ray, Diagnostic,X-Rays, Diagnostic
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D003085 Colic A clinical syndrome with intermittent abdominal pain characterized by sudden onset and cessation that is commonly seen in infants. It is usually associated with obstruction of the INTESTINES; of the CYSTIC DUCT; or of the URINARY TRACT. Abdominal Cramps,Infantile Colic,Abdominal Cramp,Colic, Infantile,Cramp, Abdominal,Cramps, Abdominal
D006579 Heterozygote An individual having different alleles at one or more loci regarding a specific character. Carriers, Genetic,Genetic Carriers,Carrier, Genetic,Genetic Carrier,Heterozygotes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077409 Tamsulosin A sulfonamide derivative and adrenergic alpha-1 receptor antagonist that is used to relieve symptoms of urinary obstruction caused by BENIGN PROSTATIC HYPERPLASIA. 5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide,Flomax,LY 253352,LY-253352,Tamsulosin Hydrochloride,YM 617,YM-617

Related Publications

Matteo Arancio, and Stefania Ranzoni, and Alessandro Delsignore, and Giuseppe Landi, and Nicola Maffei, and Maurizio Marcato, and Alessandro Mina, and Carlo Martinengo
September 2021, Hinyokika kiyo. Acta urologica Japonica,
Matteo Arancio, and Stefania Ranzoni, and Alessandro Delsignore, and Giuseppe Landi, and Nicola Maffei, and Maurizio Marcato, and Alessandro Mina, and Carlo Martinengo
May 1992, Lancet (London, England),
Matteo Arancio, and Stefania Ranzoni, and Alessandro Delsignore, and Giuseppe Landi, and Nicola Maffei, and Maurizio Marcato, and Alessandro Mina, and Carlo Martinengo
May 1992, Lancet (London, England),
Matteo Arancio, and Stefania Ranzoni, and Alessandro Delsignore, and Giuseppe Landi, and Nicola Maffei, and Maurizio Marcato, and Alessandro Mina, and Carlo Martinengo
May 1992, Lancet (London, England),
Matteo Arancio, and Stefania Ranzoni, and Alessandro Delsignore, and Giuseppe Landi, and Nicola Maffei, and Maurizio Marcato, and Alessandro Mina, and Carlo Martinengo
November 1983, The Journal of urology,
Matteo Arancio, and Stefania Ranzoni, and Alessandro Delsignore, and Giuseppe Landi, and Nicola Maffei, and Maurizio Marcato, and Alessandro Mina, and Carlo Martinengo
July 1992, Lancet (London, England),
Matteo Arancio, and Stefania Ranzoni, and Alessandro Delsignore, and Giuseppe Landi, and Nicola Maffei, and Maurizio Marcato, and Alessandro Mina, and Carlo Martinengo
April 1992, Lancet (London, England),
Matteo Arancio, and Stefania Ranzoni, and Alessandro Delsignore, and Giuseppe Landi, and Nicola Maffei, and Maurizio Marcato, and Alessandro Mina, and Carlo Martinengo
December 1994, Hinyokika kiyo. Acta urologica Japonica,
Matteo Arancio, and Stefania Ranzoni, and Alessandro Delsignore, and Giuseppe Landi, and Nicola Maffei, and Maurizio Marcato, and Alessandro Mina, and Carlo Martinengo
February 1987, The Journal of urology,
Matteo Arancio, and Stefania Ranzoni, and Alessandro Delsignore, and Giuseppe Landi, and Nicola Maffei, and Maurizio Marcato, and Alessandro Mina, and Carlo Martinengo
October 1988, The Quarterly journal of medicine,
Copied contents to your clipboard!